DDInter741 DDInter915
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Zafirlukast {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Vemurafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Flibanserin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Vemurafenib {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Flibanserin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Crizotinib {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Flibanserin {u} may lead to a major life threatening interaction when taken with {v} Loperamide
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Flibanserin {u} may lead to a major life threatening interaction when taken with {v} Loperamide
Loperamide {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Flibanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) upregulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Flibanserin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Flibanserin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Flibanserin may lead to a major life threatening interaction when taken with Loperamide and Loperamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Flibanserin may lead to a major life threatening interaction when taken with Loperamide and Loperamide (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Indacaterol (Compound)
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) upregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)